Avixgen, US Biotech Firm Ink USD 360 Mn Deal for Next-Gen Drug Delivery Platform
Avixgen has signed a licensing-out agreement worth approximately USD 360 million with a US biotechnology company for its next-generation drug delivery platform, ACP (Advanced Cell Penetrating Peptide).
Licensing-out Agreement | 19/08/2025 | By Dineshwori | 280
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy